Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes
Zeidan A, Gilligan A, Gautam S, Grinblatt D, Elsouda D, Sullivan L, Pandya B. Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136366.Peer-Reviewed Original ResearchFLT3 tyrosine kinase inhibitorsAcute myeloid leukemiaTyrosine kinase inhibitorsMedian overall survivalOverall survivalFLT3 mutation statusTreatment patternsR settingTKI useAML patientsFMS-like tyrosine kinase 3 (FLT3) mutationsMutation statusDiagnosis of AMLTyrosine kinase 3 mutationsElectronic medical record dataEligible adult patientsHigh-intensity chemotherapyOngoing retrospective studyPost-treated patientsAstellas PharmaRetrospective cohort studySystemic anticancer therapyKaplan-Meier analysisReal-world treatmentTesting trends